28.79
1.67%
-0.49
After Hours:
29.41
0.62
+2.15%
Galapagos Nv Adr stock is traded at $28.79, with a volume of 59,262.
It is down -1.67% in the last 24 hours and down -1.13% over the past month.
See More
Previous Close:
$29.28
Open:
$28.9
24h Volume:
59,262
Relative Volume:
0.40
Market Cap:
$1.69B
Revenue:
$286.00M
Net Income/Loss:
$305.47M
P/E Ratio:
-12.29
EPS:
-2.3434
Net Cash Flow:
$-492.33M
1W Performance:
-1.64%
1M Performance:
-1.13%
6M Performance:
-10.59%
1Y Performance:
-16.67%
Galapagos Nv Adr Stock (GLPG) Company Profile
Galapagos Nv Adr Stock (GLPG) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-02-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
Mar-28-24 | Downgrade | BofA Securities | Neutral → Underperform |
Mar-07-24 | Resumed | Morgan Stanley | Equal-Weight |
Aug-24-23 | Downgrade | Citigroup | Buy → Neutral |
May-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
Jan-23-23 | Upgrade | Jefferies | Underperform → Hold |
Nov-07-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jan-27-22 | Upgrade | Citigroup | Neutral → Buy |
Aug-19-21 | Downgrade | Barclays | Overweight → Equal Weight |
Aug-06-21 | Downgrade | Deutsche Bank | Buy → Hold |
Apr-20-21 | Initiated | Deutsche Bank | Buy |
Apr-14-21 | Upgrade | Barclays | Equal Weight → Overweight |
Feb-23-21 | Upgrade | BofA Securities | Underperform → Neutral |
Feb-19-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
Feb-11-21 | Downgrade | Citigroup | Buy → Neutral |
Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Nov-19-20 | Initiated | Maxim Group | Buy |
Oct-21-20 | Downgrade | Goldman | Neutral → Sell |
Aug-25-20 | Downgrade | Jefferies | Buy → Hold |
Aug-24-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
Aug-19-20 | Downgrade | Barclays | Overweight → Equal Weight |
Aug-19-20 | Upgrade | Citigroup | Neutral → Buy |
Jul-10-20 | Downgrade | Stifel | Buy → Hold |
Mar-30-20 | Upgrade | Jefferies | Hold → Buy |
Mar-18-20 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
Feb-25-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Feb-24-20 | Downgrade | BofA/Merrill | Neutral → Underperform |
Feb-20-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
Jan-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
Dec-18-19 | Downgrade | Citigroup | Buy → Neutral |
Dec-17-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
Dec-02-19 | Initiated | BofA/Merrill | Neutral |
Sep-09-19 | Resumed | Morgan Stanley | Overweight |
Jul-31-19 | Upgrade | UBS | Neutral → Buy |
Jul-29-19 | Downgrade | Jefferies | Buy → Hold |
View All
Galapagos Nv Adr Stock (GLPG) Latest News
Galapagos receives transparency notification from EcoR1 Capital - GlobeNewswire Inc.
Leerink Partners gives Market Perform rating to Galapagos NV stock, flags R&D challenges - Investing.com
Galapagos receives transparency notification from FMR LLC - GlobeNewswire Inc.
Navigating GLPG Stock: Galapagos NV ADR Journey - The InvestChronicle
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket - Benzinga
Morgan Stanley cuts Galapagos NV target to $32 from $35 - Investing.com
Earnings call: Galapagos focuses on oncology and immunology in H1 2024 report - Investing.com
Belgium stocks higher at close of trade; BEL 20 up 1.37% - Investing.com
Treasuries slip, dollar firm as markets grapple with US politics By Reuters - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.90% - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.24% By Investing.com - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.32% By Investing.com - Investing.com
Galapagos NV shares poised for outperformance, says TD Cowen - Investing.com India
Galapagos NV shares poised for outperformance, says TD Cowen By Investing.com - Investing.com
Galapagos presenteert bemoedigende nieuwe resultaten voor CD19 CAR-T kandidaat GLPG5101 in non-Hodgkin lymfoom op EHA 2024 - GlobeNewswire Inc.
Belgium stocks lower at close of trade; BEL 20 down 0.79% By Investing.com - Investing.com
Belgium shares lower at close of trade; BEL 20 down 0.79% - Investing.com India
Belgium stocks higher at close of trade; BEL 20 up 1.28% By Investing.com - Investing.com
Belgium shares higher at close of trade; BEL 20 up 1.28% - Investing.com India
Belgium stocks lower at close of trade; BEL 20 down 0.40% By Investing.com - Investing.com
Belgium shares lower at close of trade; BEL 20 down 0.40% - Investing.com India
Adaptimmune and Galapagos partner on cancer therapy By Investing.com - Investing.com
Adaptimmune and Galapagos partner on cancer therapy - Investing.com India
Adaptimmune and Galapagos partner on cancer therapy - Investing.com
Galapagos creates new subscription right plans - GlobeNewswire Inc.
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S. - GlobeNewswire Inc.
Are Medical Stocks Lagging Galapagos (GLPG) This Year? - Yahoo Singapore News
Earnings call: Galapagos outlines strategic focus in Q1 2024 results - Investing.com
Biotech Stock Roundup: ALXN Up on Acquisition News, PFE-BNTX Get EUA for Vaccine & More - Yahoo News UK
Galapagos’ aandeelhouders keuren alle door de Raad van Bestuur voorgestelde besluiten goed op de jaarlijkse Gewone en Buitengewone Algemene Aandeelhoudersvergaderingen 2024 - GlobeNewswire Inc.
Down -9.97% in 4 Weeks, Here's Why You Should You Buy the Dip in Galapagos (GLPG) - Zacks Investment Research
Insight venture partners executives sell over $61 million in nCino shares By Investing.com - Investing.com
Bristol Myers (BMY) Reports Positive Colorectal Cancer Study Data - Zacks Investment Research
Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress - Zacks Investment Research
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024 - GlobeNewswire Inc.
Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70% - Zacks Investment Research
After Plunging -7.94% in 4 Weeks, Here's Why the Trend Might Reverse for Galapagos (GLPG) - Zacks Investment Research
Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion - Zacks Investment Research
Disc Medicine (IRON) Down on Mixed Results From AURORA Study - Zacks Investment Research
Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why - Zacks Investment Research
Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst - Benzinga
Allied Gaming & Entertainment insider buys shares worth over $456,000 By Investing.com - Investing.com
Morgan Stanley sets Galapagos stock at equalweight, $38 price target By Investing.com - Investing.com
Merck's (MRK) Chronic Cough Drug Gets Another CRL From FDA - Yahoo Finance
Morgan Stanley lists biotechs with negative enterprise value, 2022 catalysts (NASDAQ:GLPG) - Seeking Alpha
Galapagos Surges On New CEO and Upgrade News - Investing.com
Galapagos: Market Values Pipeline Below $0 (NASDAQ:GLPG) - Seeking Alpha
Galapagos Begins Dosing With GLPG3970 in Psoriasis Study - Yahoo Singapore News
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs - Benzinga
The Week Ahead In Biotech: Spotlight On Gilead, BioMarin FDA Decisions, IPOs - Yahoo Finance
The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares - Yahoo Finance
Galapagos Nv Adr Stock (GLPG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):